绣春刀
拜登签行政命令，美国要推动生物技术进步！专家：中国CXO企业优势得天独厚_王文华_康德_我的网站
一 | Jaideep Ahlawat reflected on the complexity of returning to a character in a sequel at the Filmfare OTT Awards 2025, co-powered by Hyundai in association with Amanté’s press conference. To emphasise the same, he referenced his fan-favourite character Hathiram Chaudhary from Paatal Lok as a prime example. He recalled a defining moment from Season 1, where Hathiram describes the system as something that appears shabby on the outside but functions as a “well-oiled machine” within. He went on to recall how the character’s understanding was of a place where only the lever changes, never the machine. That understanding, Ahlawat said, shapes Hathiram’s worldview: no matter how hard he tries, he remains a tiny cog in a massive, unchanging structure. Picking up the character three years later in Season 2 presented its own challenges. Ahlawat explained that Hathiram is still stuck in the same chair, still the smallest part of the same system. The real task, he said, was portraying the “three-year fatigue”. This fatigue was growing with the boredom, the emotional distance from Ansari, and the ever-evolving but strained bond with his son. He recalled how, in the early episodes, Hathiram even steps into the background as Ansari rises in rank. However, his instinct as a top-tier investigator never truly fades. View this post on Instagram A post shared by Filmfare (@filmfare) Ahlawat went on to note that despite Hathiram’s frustration and reluctance, the moment a case takes an unexpected turn, “the investigating officer inside him wakes up,” driven not by ambition but by an irrepressible need for the truth. The actor highlighted the difficulty of balancing that very contradiction: a man who is exhausted by the system. And despite that, he is unable to exist without the thrill of uncovering what lies beneath. As the season progresses, Hathiram enters a space where he has no authority, no familiarity with the terrain, no power whatsoever. Yet he keeps going, only to find that, in the end, nothing changes. He returns to the same system, the same roles, the same limitations. “That’s the challenge of a sequel,” Ahlawat said. “The surprise is gone, and now the character must grow without losing what made him who he is.” This complexity is why he believes that sequels will always be harder to imagine and create than the first season of a show. The Filmfare OTT Awards 2025 are set to take place on 15th December 2025. Keep watching this space for all the updates. Also Read: Jaideep Ahlawat Shares His Journey and Creative Insights on Filmfare OTT Showcase!。
二 |
三 | CXO是指药品从研发、临床试验、生产到上市过程中的一系列外包活动，产业链上下游包括CRO、CDMO/CMO、CSO，分别服务于医疗行业的研发外包、生产外包、销售外包三个环节。
四 | 2021年以来，国内CXO行业迎来高速发展期，持续拓展海外市场。图片来源：图虫网9月13日，时代周报记者致电多家CXO企业。凯莱英方面表示，“公司在美国主要为小分子化药方面的合作，没有生物制药方面的业务。
五 | ”博腾股份方面亦表示，在美国的业务以小分子为主，该项政策刚宣布，还没有具体举措，对公司业务尚未有实质性影响。泰格医药回应称，从目前公开消息来看，主要针对的是临床前CRO业务，对泰格医药目前业务没有影响，公司不涉及CDMO和生物医药业务。CIC灼识咨询合伙人王文华向时代周报记者解释，美国旨在鼓励本土生物制药产业发展，在细则出台之前对国内CXO企业的业绩影响尚不明朗。判断CXO行业发展趋势更侧重于基本面，此次政策影响偏向短期，对长期市场成长影响不大。王文华解释，国内CXO企业在生物制药的外包服务方面的优势得天独厚。其一，国内CXO企业的人力成本较低，且有充足的化学、药学等科研人员储备；其二，中国是全球最大的原料药生产国；其三，中国庞大的人口基数与充足的患者病例资源，国内CXO在临床阶段可针对各类细分疾病做到快速大量入组，加快新药研发进度。
六 | 王文华还指出，国内CXO企业是国外生物制药企业的理想合作对象。近年，国内CXO企业在手订单飞速增长、海外市场份额持续提升。“国内CXO企业长期会经历持续稳定的市场空间拓展。” 王文华说。去年以来，国内CXO行业业绩增长强劲。2022年上半年，主要CXO公司的营收、净利均呈现稳定增长趋势。
七 | 与此同时，多家CXO主要收入也多来自国外市场。西南证券研报数据显示，在CXO板块的16家代表性企业中，2022年上半年合计收入426亿元，上涨73.2%；归母净利润约118.4亿元，涨86.6%；扣非归母净利润约95.9亿元，涨104.5%。
八 | 药明康德是CXO板块龙头，目前市值2260.22亿元。
九 | 药明康德通过全球32个营运基地和分支机构，为来自全球超5850家客户提供服务。2022年年中报显示，报告期内，药明康德实现营收177.56亿元，同比上涨68.52%；扣非净利润38.5亿元，同比上涨81%。其中，药明康德来自美国客户收入为119.09亿元人民币，同比增长104%，占总营收67.07%。9月13日上午，药明康德方面回应称，目前，公司业务和运营一切正常。2022年上半年，康龙化成营业收入46.35亿元，同比上涨41.06%。随着国际化战略的推进，公司在英国和美国共有11个运营实体，超过1300名员工。2022年上半年，海外子公司营业收入占公司营业收入的12.14%。
十 | 同期，博腾股份营收39.14亿元，同比上涨211.67%。2022年中报显示，公司于2017年收购的J-STAR，已在美国拥有2个研发厂地，能够承接临床早期原料药CRO及制剂服务。2022年上半年，J-STAR实现营业收入1.31亿元，同比增长22%。
十一 | 返回搜狐，查看更多责任编辑：
Current article:http://wsd22.tibiantasangnenti.buzz/list_7dwkcl3/szfb.html
Published on:07:46:11
